Factors that further contribute to resistance include the absence of pre-existing antitumor immunity, compensatory expression of alternative immune checkpoints, and tumour-intrinsic factors such as activation of the β-catenin pathway or loss of PTEN [63]. The gene discussed is PTEN; the disease is neoplasm.